Ontology highlight
ABSTRACT:
PROVIDER: PRJNA143999 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:This SuperSeries is composed of the following subset Series: GSE30064: Cultured human amniotic fluid-derived mesenchymal stromal cells [PIQOR data] GSE30065: Cultured human amniotic fluid-derived mesenchymal stromal cells [miRXplore data] Refer to individual Series
2011-06-18 | E-GEOD-30066 | biostudies-arrayexpress
Project description:Cultured human amniotic fluid-derived mesenchymal stromal cells [PIQOR data]
| PRJNA155153 | ENA
Project description:Cultured human amniotic fluid-derived mesenchymal stromal cells [miRXplore data]
| PRJNA155155 | ENA
Project description:The raw files of the proteomics dataset are N=18 and a brief description of the files is shown below:
AF1 raw: exosomes derived from Amniotic Fluid-Mesenchymal Stromal cells 1
AF2.raw: exosomes derived from Amniotic Fluid-Mesenchymal Stromal cells 2
AFA1.raw: exosomes derived from Amniotic Fluid-Mesenchymal Stromal cells 3
AFA2.raw: exosomes derived from Amniotic Fluid-Mesenchymal Stromal cells 4
AFB1.raw: exosomes derived from Amniotic Fluid-Mesenchymal Stromal cells 5
AFB2.raw: exosomes derived from Amniotic Fluid-Mesenchymal Stromal cells 6
HL1A.raw: exosomes derived from Hepatocyte like cells 1
HL1B.raw: exosomes derived from Hepatocyte like cells 2
HL2A.raw: exosomes derived from Hepatocyte like cells 3
HL2B.raw: exosomes derived from Hepatocyte like cells 4
HL3A.raw: exosomes derived from Hepatocyte like cells 5
HL3B.raw: exosomes derived from Hepatocyte like cells 6
HPLA1.raw: exosomes derived from Hepatic Progenitor-like cells 1
HPLA2.raw: exosomes derived from Hepatic Progenitor-like cells 2
HPLB1.raw: exosomes derived from Hepatic Progenitor-like cells 3
HPLB2.raw: exosomes derived from Hepatic Progenitor-like cells 4
HPLA.raw: exosomes derived from Hepatic Progenitor-like cells 5
HPLB.raw: exosomes derived from Hepatic Progenitor-like cells 6
Raw files analysis was performed with Proteome Discoverer 1.4 (Thermo) software package, using the Sequest search engine and the Uniprot human (Homo sapiens) reviewed database, downloaded on December 15, 2017, including 20,243 entries. The search was performed using carbamidomethylation of cysteine as static and oxidation of methionine as dynamic modifications. Two missed cleavage sites, a precursor mass tolerance of 10 ppm and fragment mass tolerance of 0.05 Da were allowed. False discovery rate (FDR) validation was based on q value: target FDR : 0.05. Label free quantification was performed by utilizing the precursor ion area values exported from the total ion chromatogram as defined by the Proteome Discoverer v. 1.4.0.288 (Thermo Scientific). Output files from Proteome Discoverer were processed with R programming language for statistical computing (version 4.0.3).
The following comparisons were made: AF vs HL, AF vs HPL and HL vs HPL.
The msf files are N=18 and have the same name as the raw files above.
| MSV000092848 | MassIVE
Project description:Amniotic fluid has been proposed as an easily available source of cells for numerous applications in regenerative medicine and tissue engineering. The use of amniotic fluid cells in biomedical applications necessitates their unequivocal characterization; however, the exact cellular composition of amniotic fluid and the precise tissue origins of these cells remain largely unclear. Using cells cultured from human amniotic fluid of the second trimester from a healthy fetus and fetuses with spina bifida aperta, we have performed single-cell RNA sequencing to characterize the tissue origin and marker expression of cultured amniotic fluid cells at the single-cell level. Our analysis identified nine different cell types of stromal, epithelial and immune cell phenotype, and from various fetal tissue origins, demonstrating the heterogeneity of the cultured amniotic fluid cell population at single-cell resolution. Further, our data question the presence of pluripotent stem cell populations in cultured AF, and provide a comprehensive list of markers for the characterization of its various progenitor and terminally differentiated cell types. Our study highlights the relevance of single-cell analysis approaches for the characterization of amniotic fluid cells in order to harness their full potential in biomedical research and clinical applications.
2023-07-05 | GSE206696 | GEO
Project description:Primary epithelial cells isolated from fetal lungs of rat fetuses with or without lung hypoplasia induced by the administration of nitrofen to pregnant rats. Control group included epithelial cells from normal fetal lungs. Treatment with amniotic fluid stem cell derived extracellular vesicles or with mesenchymal stromal cell derived exosomes, RNA-seq of both cargos included.
2021-03-23 | E-MTAB-8921 | biostudies-arrayexpress
Project description:Human amniotic fluid-derived mesenchymal stromal cells (hAMSC) have become one of the main cell populations used in regenerative medicine and for the study of various clinical disorders. These cells have a great capacity for proliferation and differentiation, do not form teratomas when transplanted into animal models and their stemness seems to be between embryonic cells and adult mesenchymal cells. Prior to their use in cell therapy they must be cultured and expanded in vitro, but the effect this process has on their fitness, a determining factor for the success or failure of cell therapy, is unknown. We undertook a follow-up of gene and microRNAs (miRNAs) expression using microarray of a hAMSC population kept under in vitro culture conditions for the first 15 passages. Significant changes were noted in the expression of various mRNAs and miRNAs, particularly down-regulation of TP53, increased expression of hsa-miR-125a and up-regulation of CDKN2D. The variations in TP53 and hsa-miR-125a may act as an indicator of the stemness of the hAMSC, whereas CDKN2D may indicate the reduction in the proliferative capacity of these cells in a TP53-independent mechanism. The genes described in this study will help evaluate the fitness of hAMSC, thus guaranteeing their biological quality for use in regenerative medicine. miRNA patterns were studied in in vitro culture samples of human amniotic fluid-derived mesenchymal stromal cells at passages P1, P3, P5 and P10 with miRXplorer microarrays using a synthetic pool of miRNAs. Cell pellets of 5 x 10E5 cells were cryopreserved in liquid nitrogen and sent to Miltenyi Biotec for their analysis.
2011-06-18 | E-GEOD-30065 | biostudies-arrayexpress
Project description:Mesenchymal stromal cells (MSC) are currently being evaluated in numerous preclinical and clinical cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modelling, pharmaceutical screening and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources, restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low volumes of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming.
2017-08-31 | GSE101602 | GEO
Project description:Transcriptional profiling of human amniotic fluid-derived mesenchymal stem cells (AF-MSCs) comparing normal condition-cultured AF-MSCs with hypoxia condition-culture AF-MSCs ES cells. The latter improves the proliferation and survival of AF-MSCs, and makes AF-MSCs secret more growth factors. Goal was to determine the effects of hypoxia condition on global AF-MSCs gene expression.
2013-12-18 | GSE53402 | GEO
Project description:Human amniotic fluid-derived mesenchymal stromal cells (hAMSC) have become one of the main cell populations used in regenerative medicine and for the study of various clinical disorders. These cells have a great capacity for proliferation and differentiation, do not form teratomas when transplanted into animal models and their stemness seems to be between embryonic cells and adult mesenchymal cells. Prior to their use in cell therapy they must be cultured and expanded in vitro, but the effect this process has on their fitness, a determining factor for the success or failure of cell therapy, is unknown. We undertook a follow-up of gene and microRNAs (miRNAs) expression using microarray of a hAMSC population kept under in vitro culture conditions for the first 15 passages. Significant changes were noted in the expression of various mRNAs and miRNAs, particularly down-regulation of TP53, increased expression of hsa-miR-125a and up-regulation of CDKN2D. The variations in TP53 and hsa-miR-125a may act as an indicator of the stemness of the hAMSC, whereas CDKN2D may indicate the reduction in the proliferative capacity of these cells in a TP53-independent mechanism. The genes described in this study will help evaluate the fitness of hAMSC, thus guaranteeing their biological quality for use in regenerative medicine. The variations in the expression patterns of the mRNAs were studied using topic-defined PIQOR Stem Cell microarrays. Human amniotic fluid-derived mesenchymal stromal cells pellets of 5 x 10E5 cells were cryopreserved in liquid nitrogen and send to Miltenyi Biotec for their analysis. A pool of non-stimulated lymphocytes (non-mitotic cell cycle) obtained by Ficoll isolation in the Immunology Service of Carlos Haya hospital was used as a control of the expression.
2011-06-18 | E-GEOD-30064 | biostudies-arrayexpress